Van Cutsem, E, Danielewicz, I, Saunders, M P, Pfeiffer, P, Argiles, G, Borg, C, Glynne-Jones, R, Punt, C J A, van de Wouw, A J, Fedyanin, M, Stroyakovskiy, D, Kroening, H, Garcia-Alfonso, P, Wasan, H S, Falcone, A, Aubel, P, Egorov, A, Amellal, N & Moiseenko, V 2021, ' Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival. ', Journal of Clinical Oncology, vol. 39, no. Suppl. 3, pp. 14-14 . https://doi.org/10.1200/JCO.2021.39.3suppl.14